Inequalities in care persist across Europe for people living with dysimmune inflammatory neuropathies (CIDP, MMN, MADSAM, Auto-immune Nodopathies, Anti-MAG neuropathies, GBS MFS…). Access to timely diagnosis, established and innovative treatments, continuous access to therapy, and appropriate long-term follow-up remains uneven across Member States.
EPODIN advocates for equitable access to care and innovation across Europe.
We work to promote a seamless, coordinated and patient-centred care pathway — from clinical research to sustained access to treatments — with the aim of improving continuity of care and the quality of life of patients.
EPODIN works to ensure that European public health policies take into account the specific needs of people affected by dysimmune and inflammatory neuropathies (DINs : CIDP, MMN, LSS, Anti-MAG, GBS, MFS…). We are fully committed working with Member States, MEPs and European Commission in the interest of patients.
